ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3-5: A Network Meta-Analysis of Randomised Clinical Trials.

Y, Zhang; D, He; W, Zhang; Y, Xing; Y, Guo; F, Wang; J, Jia; T, Yan; Y, Liu; S, Lin

doi:10.1007/s40265-020-01290-3

Public

ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3-5: A Network Meta-Analysis of Randomised Clinical Trials.

Shared by NobleBlocks on Jun 1, 2020 • 12:00 AM UTC

Authors:

Zhang Y

He D

Zhang W

Abstract

<h4>Background</h4>The advantages of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) in reducing risk of cardiovascular events (CVEs) and delaying end-stage kidney disease (ESKD) in patients with chronic kidney disease (CKD) is well-known. However, the eff...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!